/PRNewswire/ KAHR, a clinical-stage biotech company developing DSP107, a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and.
/PRNewswire/ KAHR, a clinical-stage biotech company developing a novel, bi-specific CD47x4-1BB targeting immunotherapy that activates innate and adaptive.
Peregrine Ventures invests in US cancer therapy co globes.co.il - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globes.co.il Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
JERUSALEM, April 1, 2021 /PRNewswire/ KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced today that it has entered into a licensing agreement with Thomas Jefferson University a national doctoral research university and its clinical enterprise, Jefferson Health, located in Philadelphia, PA. Under the agreement, Thomas Jefferson University is granting KAHR an exclusive license to develop and commercialize multiple new drug candidates including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein for immuno-oncology. With this agreement we are adding a second fusion protein platform to our portfolio, enabling us to broaden our immuno-oncology target pipeline and positioning KAHR as a world leader in the fusion protein space, said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. Both DSP502 and DSP216 focus on promising checkpoint pathways, unleashing